The effects of dopamine D1 and D2 receptor agonists and antagonists in monkeys withdrawn from long-term neuroleptic treatment
References (20)
The discriminative stimulus properties of the D-1 agonist SKF 38393 and the D-2 agonist (−)-NPA are mediated by separate mechanisms
Life Sci.
(1988)- et al.
Pharmacological effects of a specific dopamine D-1 antagonist SCH 23390 in comparison with neuroleptics
Life Sci.
(1984) - et al.
Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration
Pharmacol. Biochem. Behav.
(1986) - et al.
Selective D-2 dopamine receptor agonists prevent catalepsy induced by SCH 23390, a selective D-1 receptor antagonist
Life Sci.
(1985) - et al.
Induction of oral dyskinesias in naive rats by D-1 stimulation
Life Sci.
(1983) Behavioural correlates of the action of selective D-1 dopamine receptor antagonists
Biochem. Pharmacol.
(1986)Therapeutic potential of selective D-1 dopamine receptor agonists in psychiatry and neurology
Gen. Pharmacol.
(1988)- et al.
Dopamine D-1 and D-2 receptor differentiation revealed by behavioural studies in rats
- et al.
Relative dopamine D-1 or D-2 receptor affinity and efficacy determine whether dopamine agonist induce hyperactivity or oral stereotypy in rats
Pharmacol. Toxicol.
(1988) - et al.
Acute extrapyramidal syndrome in Cebus monkeys; devolopment mediated by dopamine D2 but not D1 receptors
J. Pharmacol. Exp. Ther.
(1989)
Cited by (50)
Effects of cannabinoid CB<inf>1</inf> receptor agonism and antagonism on SKF81297-induced dyskinesia and haloperidol-induced dystonia in Cebus apella monkeys
2011, NeuropharmacologyCitation Excerpt :While acute dystonia is associated with excessive antagonism of D2 receptors, oral dyskinesia induced by chronic treatment with antipsychotic drugs is believed to involve sensitisation of both D2 and D1 receptors, with a prominent role for D1 receptors (reviewed by Kostrzewa et al., 2007 and Ossowska, 2002). The involvement of D1 receptors in dyskinesia is supported by studies showing that D1-selective agonists induce dyskinesia in rats (e.g. Ellison et al., 1988; Rosengarten et al., 1983) and monkeys (Lublin et al., 1992, Lublin, 1995; Peacock et al., 1990), as well as by recent biochemical and genetic evidence (Carta et al., 2008; Darmopil et al., 2009; Gerfen, 2003). Cannabis is among the most frequently abused drugs by patients with schizophrenia (Kavanagh et al., 2004; Margolese et al., 2004), and hypotheses on self-medication have been proposed (Negrete, 2003).
Primate models of dystonia
2009, Progress in NeurobiologyThe differential effects of 5-HT<inf>1A</inf> receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat
2007, Brain ResearchCitation Excerpt :Thus the paramount goal of the present study was to characterize the effects of 5-HT1AR stimulation on D1R- and D2R-mediated behaviors. In order to accomplish this goal, we employed the D1R agonist, SKF81297 (Peacock et al., 1990) and the D2R agonist, quinpirole (Tsuruta et al., 1981) at doses that appear to produce equivalent AIMs expression. Numerous studies have implicated D1 receptors in dyskinesia expression and development.
Neuroleptic-induced acute dystonia and tardive dyskinesia in primates
2005, Movement DisordersNeuroleptic-Induced Acute Dystonia and Tardive Dyskinesia in Primates
2004, Movement Disorders: Genetics and Models: Second EditionThe effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia
2004, Pharmacology Biochemistry and Behavior